GlaxoSmithKline

Concerns over pricey equity markets and the risks of value traps have pushed investment opportunities to their lowest level for seven years, according to the co-manager of the Kennox Strategic Value fund.

EQUITIES

The FTSE 100 has ended three straight days of losses to move 0.9% higher, returning to levels last seen at the end of May.

Pharmaceutical giant GlaxoSmithKline spent over £320m bribing Chinese doctors to prescribe its products, according to the country's police.

UK equity income funds are nearing single stock limits on key holdings, causing concentration risk fears to mount, but which funds are taking the biggest bets?

Henderson Global Investors has reopened its UK Absolute Return strategy, managed by ex-Gartmore duo Luke Newman and Ben Wallace, Investment Week can reveal.

After a decade of scant gains, some investors are now piling into pharmaceuticals as a combination of high yields and attractive valuations draw managers in, but is this the start of a decade-long move up?

Fidelity's Michael Clark has warned against buying into BP and Shell amid a dwindling oil price and ongoing issues for both businesses.

EQUITIES

Standard Life Investments' Thomas Moore, manager of the £105m UK Equity Income Unconstrained fund, has sold out of UK pharmaceuticals amid fears the sector faces further earnings downgrades this year.